Most Read Articles
01 Oct 2013

Heart disease is still New Zealand’s biggest killer, with one Kiwi dying from coronary heart disease every 90 minutes. Pharmacy Today New Zealand looks at how pharmacists can help

Dr. James Salisi, 01 Jul 2014

The recent spike in the number of new cases of human immunodeficiency virus (HIV) infection in the Philippines means that clinicians and pharmacists alike may need to increase their awareness and competency in prescribing and monitoring HIV treatment. Although taught in medical and pharmacy schools, the scarcity in exposure to clinical cases before highlights the need to for physicians and pharmacist to review HIV pharmacotherapy in order to cater to the increasing HIV patient population.

01 Sep 2017
Complementary medicines can play an important part in maintaining wellness, preventing deficiencies and optimizing health outcomes, says Dr Lesley Braun PhD, Director of the Blackmores Institute. 
08 Oct 2017
Tumour necrosis factor inhibitors (TNFIs) may inhibit spinal radiographic progression in patients with ankylosing spondylitis (AS) through the inhibiting effect of the drugs on disease activity, a study suggests.

Product Highlight – Dukoral

12 Jul 2017
DUKORAL – Inactivated Vibrio cholerae O1 serogroup & recombinant cholera toxin B subunit (WC/rCTB) vaccine (oral) – AJ Biologics

The Drinkable Vaccine against Cholera & enterotoxigenic E.coli (ETEC) Diarrhoea


Clinically proven protective efficacy:
- Up to 85-90% against cholera in the first 6 months3,4,6
- Up to 67% against ETEC in the first 3 months.5

At least one week interval between doses. Primary immunization can be completed as early as 8 days for adults and children over 6 years old (2 required doses) and 15 days for children 2-6 years (3 required doses).1

Onset of protection starts 7 days after completion of immunisation. The vaccination course should be completed at least one week before traveling.1

Good safety profile with most frequently reported adverse reactions occurred at similar frequencies in vaccine and placebo group in studies.

References:

1. DUKORAL full prescribing information (SV40398_MY).
2. Clements JD, Finkelstein RA. Demonstration of shared and unique immunological determinants in enterotoxins from Vibrio cholerae and Escherichia coli. Infect Immun 1978;22:709–13.
3. World Health Organization. Use of Oral Cholera Vaccine in Humanitarian Emergencies. http://www.who.int/cholera/vaccines/OCV_in_humanitarian_emergencies_15Jan2014.pdf.
4. Clemens JD, Sack DA, Harris RJ et al. Field trial of oral cholera vaccines in Bangladesh. Lancet 1986, 2:124-7.
5. Clemens JD., et al. Cross-protection by B subunit whole-cell cholera vaccine against diarrhoea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: result of a large-scale field trial. J Infect Dis 1988; 158:372-77.
6.
World Health Organization. Cholera vaccines WHO position paper. Weekly Epidemiologic Record (WER). No 13, 2010, 85, 117-128 http://www.who.int/wer/2010/wer8513.pdf.

Further information is available in section 12b, New in This Issue and mims.com
Full prescribing information is available upon request.

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
01 Oct 2013

Heart disease is still New Zealand’s biggest killer, with one Kiwi dying from coronary heart disease every 90 minutes. Pharmacy Today New Zealand looks at how pharmacists can help

Dr. James Salisi, 01 Jul 2014

The recent spike in the number of new cases of human immunodeficiency virus (HIV) infection in the Philippines means that clinicians and pharmacists alike may need to increase their awareness and competency in prescribing and monitoring HIV treatment. Although taught in medical and pharmacy schools, the scarcity in exposure to clinical cases before highlights the need to for physicians and pharmacist to review HIV pharmacotherapy in order to cater to the increasing HIV patient population.

01 Sep 2017
Complementary medicines can play an important part in maintaining wellness, preventing deficiencies and optimizing health outcomes, says Dr Lesley Braun PhD, Director of the Blackmores Institute. 
08 Oct 2017
Tumour necrosis factor inhibitors (TNFIs) may inhibit spinal radiographic progression in patients with ankylosing spondylitis (AS) through the inhibiting effect of the drugs on disease activity, a study suggests.